跳至主要内容
临床试验/NL-OMON52126
NL-OMON52126招募中不适用

Vaccination Against Covid in Primary Immune Deficiencies - VACOPID

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 700 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
700

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • Subjects must meet the Inclusion Criteria for enrollment into the study.
  • Subjects are eligible for the study if all of the following apply:
  • 1. All patients should be eligible for COVID-19 vaccination as described by the
  • instructions of the manufacturer.
  • 2. Age of 18 years or older
  • 3. Capable of understanding the purpose and risks of the study, fully informed
  • and given written informed consent (signed informed consent form has been
  • 4. A diagnosis of either one of the IUIS criteria based diagnoses below:
  • - CVID, with or without use of immunosuppressive therapy
  • - Selective IgG subclass deficiency
  • - Partners, sibling or other family member from patient (not suffering from a

排除标准

  • A potential subject who meets any of the following criteria will be excluded
  • from participation in this study:
  • History of severe adverse reaction associated with a vaccine and/or severe
  • allergic reaction (e.g., anaphylaxis) to any component of the study
  • intervention(s).
  • Women who are pregnant or breastfeeding
  • Active (hematological) malignancy
  • HIV (Human Immunodeficiency Virus)
  • Bleeding diathesis or condition associated with prolonged bleeding that would,
  • in the opinion of the investigator, contraindicate intramuscular injection.

研究者

相似试验

Vaccination Against Covid in Primary Immune... | 临床试验